Archives of Medical Research
Volume 40, Issue 7 , Pages 536-544, October 2009

Effect of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitor (Vildagliptin) on Peripheral Nerves in Streptozotocin-induced Diabetic Rats

  • Heung Yong Jin
  • ,
  • Wei Jing Liu
  • ,
  • Ji Hyun Park
  • ,
  • Hong Sun Baek
  • ,
  • Tae Sun Park

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Tae Sun Park, M.D., Ph.D., Division of Endocrinology and Metabolism, Department of Internal Medicine, Chonbuk National University Medical School, 634-18, Keum-Am Dong, Jeonju, 561-712, South Korea; Phone: 82-63-250-1794; FAX: 82-63-254-1609

Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, South Korea

Received 26 June 2009; accepted 7 September 2009.

(ARCMED-D-09-00310)

Background and Aims

The aim of this study was to investigate the GLP-1 pathway effect on peripheral nerves using a DPP-IV inhibitor in streptozotocin (STZ)-induced diabetic rats.

Methods

Adult male Sprague Dawley rats were divided into four groups and two groups (n=6 in each) were given a DPP-IV inhibitor of 0.3mg/kg/day or 10mg/kg/day dissolved in water. Intraepidermal innervation was quantified as nerve fiber abundance per unit length of epidermis (IENF/mm) following an immunohistochemical procedure using the polyclonal antibody of anti-protein gene product 9.5 (PGP 9.5).

Results

Daily administration of DPP-IV inhibitor to the experimental diabetes model at doses of 10mg/kg for 32 weeks protected nerve fiber loss compared with untreated rats as follows (IENF/mm): normal (9.89±0.34), diabetes mellitus (DM) (8.42±0.28), DM with 0.3mg/kg DPP-IV inhibitor (9.88±0.38), and DM with 10mg/kg DPP-IV inhibitor (10.36±0.32) (p<0.05). There was a significant reduction (% change) in the decrease of intraepidermal nerve fiber density (IENFD) in the DPP-IV inhibitor-treated groups during the experimental period: normal (10.1%), DM (25.8%), DM with 0.3mg/kg DPP-IV inhibitor (13.3%), and DM with 10mg/kg DPP-IV inhibitor (7.9%) (p<0.05).

Conclusions

Our study suggests that a DPP-IV inhibitor may prevent peripheral nerve degeneration in a diabetes-induced animal model and support the idea that GLP-1 may be useful in peripheral neuropathy.

Key Words: DPP-IV inhibitor, Diabetes, GLP-1 pathway, Peripheral nerve

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Conflict of interest: None

PII: S0188-4409(09)00182-9

doi:10.1016/j.arcmed.2009.09.005

Archives of Medical Research
Volume 40, Issue 7 , Pages 536-544, October 2009